Telesis Bio (TBIO) announced a new license agreement with Regeneron Pharmaceuticals (REGN) to deploy Telesis Bio’s Gibson SOLA platform at its R&D core facilities. The company stated this will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs, aiming to accelerate biologics discovery timelines from weeks to hours. The Gibson SOLA platform is designed to enable fully-enzymatic, overnight, on-site synthesis of high-fidelity DNA and mRNA.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off